Scott Struthers News Today

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. A number of other equities research analysts have also recently commented on CRNX. Oppenheimer raised their […]

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Several other equities research analysts have also recently commented on CRNX. Jonestrading increased their price objective on Crinetics Pharmaceuticals […]

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. A number of other research firms have also commented on CRNX. Morgan Stanley increased […]

AJOVista LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,630 shares of the company’s stock, valued at approximately $58,000. Other institutional investors also recently added to […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 5,220,000 shares, a growth of 6.3% from the March 31st total of 4,910,000 shares. Based on an average trading volume of 802,900 shares, the days-to-cover ratio […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CEO Richard Scott Struthers sold 40,951 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the transaction, the chief executive officer now directly owns 237,835 shares in […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript February 29, 2024 Crinetics Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call. At this time […]

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target […]